Core Viewpoint - The stock price of Tigermed (300347)(03347) has shown a significant rebound after a period of decline, primarily driven by the company's earnings forecast for 2025, which has garnered market recognition for its investment-driven research strategy [1][2]. Group 1: Stock Performance - Tigermed's stock price rebounded from a low of 36.08 HKD on November 21 last year to a peak of 54.85 HKD on January 15, marking a maximum increase of 52.02% [1]. - Following a technical decline, the stock price fell below 50 HKD on January 28 but rebounded sharply on January 29 and 30, indicating a stabilization in its price trend [1]. - After the earnings forecast was released, the stock price opened higher and reached 56.25 HKD, with a trading volume of 704.77 million shares, reflecting strong buying interest from investors [3]. Group 2: Earnings Forecast - Tigermed's earnings forecast for 2025 indicates expected revenue between 6.66 billion to 7.68 billion CNY, representing a year-on-year growth of 1% to 16% [2]. - The net profit attributable to shareholders is projected to be between 830 million to 1.23 billion CNY, showing a significant increase of 105% to 204% year-on-year, primarily due to non-recurring gains [2]. - Non-recurring gains are expected to be between 500 million to 740 million CNY, contributing to the net profit increase, which is largely driven by investment income rather than core clinical CRO business [2]. Group 3: Market Sentiment and Analyst Ratings - Following the earnings announcement, Goldman Sachs adjusted its profit forecasts for Tigermed for 2025 to 2027, with target prices for H-shares and A-shares slightly increased, maintaining a "buy" rating [3]. - UBS also issued a "buy" rating with a target price of 57.1 HKD, focusing on the recovery signals in new order pricing for 2026 [3]. - The shift in trading strategy by Hong Kong Stock Connect funds towards "right-side trading" was noted, particularly after the earnings forecast was disclosed [5][7]. Group 4: Industry Trends - The domestic healthcare financing market has shown signs of recovery, with a 22% year-on-year increase in financing amounts in the first three quarters of 2025, indicating a shift towards more substantial clinical investments [10]. - The approval rates for innovative drug IND applications have improved, with a 96.5% approval rate for Class 1 innovative drugs, suggesting a more favorable regulatory environment [10][11]. - The demand for clinical CRO services is expected to rise as companies increase their clinical trial investments, benefiting leading firms in the sector like Tigermed [11].

Core Viewpoint - The stock price of Tigermed (03347) has shown a significant rebound after a period of decline, primarily driven by the company's earnings forecast for 2025, which has garnered market attention and investor interest [1][2]. Group 1: Stock Performance - Tigermed's stock price has rebounded from a low of 36.08 HKD on November 21 last year to a peak of 54.85 HKD on January 15, marking a maximum increase of 52.02% [1]. - Following a technical decline, the stock price fell below 50 HKD but rebounded sharply on January 29 and 30, indicating a stabilization in its price trend [1]. - The stock price jumped to 56.25 HKD the day after the earnings forecast was released, reflecting strong buying interest from investors [3]. Group 2: Earnings Forecast - Tigermed's earnings forecast for 2025 predicts revenue between 6.66 billion and 7.68 billion CNY, representing a year-on-year growth of 1% to 16% [2]. - The net profit attributable to shareholders is expected to be between 830 million and 1.23 billion CNY, showing a significant increase of 105% to 204% [2]. - However, the growth in net profit is largely attributed to non-recurring gains, which are expected to be between 500 million and 740 million CNY, indicating that the core business did not drive this growth [2]. Group 3: Market Sentiment and Institutional Response - Following the earnings forecast, Goldman Sachs adjusted its profit forecasts for Tigermed, lowering estimates for 2025 while slightly increasing those for 2026 and 2027, and raised the target price for its H-shares to 66.4 HKD [3]. - UBS also set a target price of 57.1 HKD for Tigermed, emphasizing the importance of monitoring new order prices and management guidance for 2026 [3]. - The trading activity in the secondary market indicates a strong buying sentiment, with a significant increase in trading volume following the earnings announcement [3]. Group 4: Industry Trends - The domestic healthcare financing market has shown signs of recovery, with a 22% year-on-year increase in financing amounts in the first three quarters of 2025, indicating a shift towards more substantial clinical investments [10]. - The approval rates for innovative drug applications have improved, with a 96.5% approval rate for INDs, suggesting a more favorable regulatory environment for clinical projects [10][11]. - The demand for clinical CRO services is expected to rise as companies increase their clinical trial investments, benefiting leading firms in the industry [11]. Group 5: Business Model and Strategy - Tigermed's strategy of "investing to support research" has proven advantageous, with new order volumes expected to grow significantly compared to the previous year [11]. - This model is not unique to Tigermed, as many CRO companies are adopting similar strategies to expand their market presence [12]. - However, this business model carries inherent risks, as fluctuations in industry conditions can impact both the core CRO business and the investment returns, leading to increased stock volatility [12].